Avantor, Inc. AVTR is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by solid first-quarter 2024 results and operational workflow also looks promising. However, headwinds resulting from the loss of a significant number of customers and forex volatility are major downsides. Over the past year, this Zacks Rank #3 (Hold) stock has rallied 0.9% compared with the 4% rise of the industry and 27.1% growth of the S&P 500. The renowned provider of mission-critical products and services has a market capitalization of $14.18 billion. The company projects 9.7% growth for the next five years and expects to witness continued improvements in its business. Avantor surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed the same in one and broke even once, delivering an earnings surprise of 5.1%, on average. Zacks Investment Research Image Source: Zacks Investment Research Let’s delve deeper. Operational Workflow: We are optimistic about Avantor’s more than 200 facilities strategically located worldwide, including manufacturing, distribution, service, research & technology and sales centers. The company operates more than 45 global manufacturing facilities, including 19 facilities that are current Good Manufacturing Practice (cGMP) compliant and have been registered with the FDA or comparable foreign regulatory authorities. Product Portfolio: We are optimistic about Avantor’s portfolio, which includes a comprehensive range of products and services that allow it to create customized and integrated solutions for its customers. This month, the company launched two innovative products that together sustainably optimize the gene therapy harvest process — J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease. Strong Q1 Results: Avantor’s management confirmed that in the first quarter of 2024, the company’s bioprocessing end market in Bioscience Production remained healthy with a robust pipeline of new therapies, a favorable regulatory landscape (including three new cell and gene therapy approvals in the quarter) and strong patient demand. AVTR also saw sequential improvement in its bioprocessing order rate. Downsides Loss of a Significant Number of Customers: Avantor’s operating results could be adversely affected by the loss of revenues from a significant number of its customers, including direct distributors and end users. If a significant number of customers purchase fewer of its products, defer orders or fail to place additional orders with the company, its sales could decline, and its operating results may not meet its expectations. Forex Volatility: A substantial amount of Avantor’s revenues is derived from international operations. Avantor also anticipates that a significant portion of its sales will continue to come from international markets in the future. The revenues reported by Avantor with respect to its operations outside of the United States may be adversely affected by fluctuations in foreign currency exchange rates. Estimate Trend Avantor has been witnessing a flat estimate revision trend for 2024. Over the past 90 days, the Zacks Consensus Estimate for its earnings per share has remained stable at $1.01. The Zacks Consensus Estimate for second-quarter 2024 revenues is pegged at $1.71 billion, which suggests a 2.2% decline from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, Stryker Corporation SYK and Ecolab Inc. ECL. DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have gained 34.7% compared with the industry’s 9.6% rise in the past year. Stryker, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.6%. SYK’s earnings surpassed estimates in each of the trailing four quarters, with the average being 4.9%. Stryker has gained 13.2% against the industry’s 3.1% decline in the past year. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%. Ecolab’s shares have rallied 31.2% against the industry’s 13.8% decline in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL):Free Stock Analysis Report Stryker Corporation (SYK):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report Avantor, Inc. (AVTR):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...